In this investigation, the clinical effectiveness of a series of two oral rinse products [Ardox-X® and Corsodyl oral rinses], each tested against a water placebo treatment, towards oral malodour (halitosis) was determined using a newly-developed, portable gas-chromatographic system with the ability to determine parts-per-billion (ppb) levels of 3 different VSCs in air directly sampled from the oral cavity. These VSC determinations were made before, and at selected diurnal time-points after treatment of participants with each of the oral rinse formulations in the recommended manner, and then compared with corresponding measurements made after they rinsed with a H2O placebo control in place of the oral rinse formulations.
Scientific report: a multifactorial investigation of the ability of oral heathcare products to combat oral malodour; Professor Martin Grootveld BSc, PhD (Lond.), FIBMS, CBiol., FSB, FRSC, Leicester School of Pharmacy, The Montfort University, Leicester, United Kingdom
The aim of this study was to determine the antimicrobial potential of Ardox-X® and the effects of a twice-daily oral rinse on dental plaque composition. After one week without brushing teeth and only using an Ardoz-X® mouthwash, the oral hygiene of participants remained relatively clean despite the lack of brushing. There was no outgrowth of gram-negative anaerobic bacteria (associated with gum diseases), but a slight promotion of harmless bacteria.
Effect of an oxygenating agent on oral bacteria in vitro and on dental plaque composition in healthy young adults; Mercedes Fernandez y Mostajo, Wil A. van der Reijden, Mark J. Buijs, Wouter Beertsen, Fridus van der Weijden, Wim Crielaard and Egija Zaura; Department of Preventive Dentistry, Academic Centre for Dentistry Amsterdam (ACTA), University of Amsterdam and Free University Amsterdam
In summary, it can be stated that the therapy concept with Ardox-X® effectively treats the multifactorial character of periodontitis as gently as possible in a double-stage procedure. Neither antibiotics nor chlorhexidine are used here. Ardox-X® is not cytotoxic and contains no peroxides or free radicals. There is no danger of building resistance. The dentist applies the highly dosed Perio Protection Gel directly into the gingival pockets by means of a ready-for-use syringe. Additionally, the patient receives the included Ardox-X® mouthwash for after-care (also available in pharmacies). The patient uses this mouthwash following the treatment for domestic care in order to maintain the level of active oxygen and to prevent reinfection.
The Effective Treatment of Periodontitis and Peri-implantitis with Innovative Oxygen Technology Author: Dr. med. dent. Deborah Horch, Düsseldorf, Germany
Objective: The aim of the study was to gain insight into the healing effects of Ardox-X® in periodontitis and peri-implantitis, through the release of active oxygen in the peri-dental and peri-implant area. The results were to be compared with the generally accepted – ‘gold standard’ – treatment strategies for these disease entities. As reported in the literature, in addition to mechanical/instrumental treatment, chlorhexidine digluconate (CHX), hydrogen peroxide (H2O2) and antimicrobials are most often prescribed and used in these situations, as well as in many other different oral and dental disorders. These medications are known to have advantageous effects, but they also have limitations, disadvantages and adverse effects.This pilot study aimed at discovering whether Ardox-X® might be a better alternative.
From the case control periodontitis study results, it could be concluded that adjunctive Ardox-X® yielded better average total pocket depth reduction percentages than generally reported in the literature for other treatment strategies. From the Ardox-X® protocol peri-implantitis study results, it could be concluded that the clinical situation around implants improved markedly within 3 to 6 weeks in all cases. After 3 months, 75% of cases were clinically cured. Radiographically evidenced re-osseointegration of 2 mm could be noted in 60% and of 3 mm in 15% of cases after 6 months. These figures are indicative of faster and better pocket and peri-implantitis healing than reported in the literature for the generally accepted – ‘gold standard’ – adjunctive treatment regimens.
Ardox-X® topical active oxygen application in periodontitis and peri-implantitis –a pilot study; Berendsen JLM, el Allati I, Sylva LH, Blijdorp PA, Meijer GJ; * Department of Oral & Maxillofacial Surgery, Rijnstate Hospital Arnhem, The Netherlands; Departments of Periodontology & Biomaterials and Oral & Maxillofacial Surgery, Radboud University Nijmegen Medical Centre, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands
Oxygen Releasing Compound: A Morphological Controlled Clinical Trial Aim of the present in vivo study is to assess if a toothpaste containing an oxygen releasing compound (AX) is able to reduce the biofilm formation on implants with rough surface compared to a control toothpaste, without affecting the microstructure of the tested surface.
Implant Surfaces Exposed to the Oral Cavity and Treated with Toothpaste Containing Oxygen Releasing Compound: A Morphological Controlled Clinical Trial; Canciani E, et al. Dent Adv Res 5: 165; Department of Biomedical Surgical and Dental Sciences, Università degli Studi di Milano, Italy
The purpose of this study was to examine the effects and tolerability of the Ardox-X® product according to clinical-dermatological test criteria.
After a four-week application period of the Ardox-X® product by subjects suffering from atopic dermatitis, a reduction of the atopic score from 17,67 to 2,72 was evaluated. This corresponded to a reduction of about 84,61% in comparison to the initial value.
This in-vivo trial evaluated the skin parameter scaling, inflammation and erythema on a group of 16 male and female subjects suffering from psoriasis who used during a period of 4 weeks a product with Ardox-X®.
From dermatological point of view it can be concluded that the product with Ardox-X®
had been very well tolerated during application after clinical-dermatological criteria and its application led to an improvement of skin scaling, inflammation and erythema up to 40%.
